Juvenile Arthritis News

Glucocorticoids alone demonstrate similar recovery rates as intravenous immunoglobin, or combination therapy with both, in patients with multisystem inflammatory syndrome in children, according to data published in The Lancet Rheumatology.

Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

SCOTTSDALE, Ariz. — The prevalence of systematic-onset juvenile idiopathic arthritis-related lung disease appears to be on the rise, and being aware of clinical manifestations is important for catching the disease early, a speaker said.

Conventional memory B cells with low CXCR5 levels and CXCR5 T-helper 2 memory cells are potential biomarkers of juvenile dermatomyositis disease activity, according to data published in Arthritis & Rheumatology.

Remission should be the primary goal for patients with childhood-onset systemic lupus erythematosus, according to new points to consider for treat-to-target endorsed by the Pediatric Rheumatology European Society.

Patients with juvenile idiopathic arthritis do not appear to have an increased risk for anxiety or depression, compared with the general population, according to data published in Pediatric Rheumatology.

Key risk factors that may predict severe disease in patients with MIS-C include fever greater than 103.1 degrees Fahrenheit, central nervous system involvement and left ventricular dysfunction, according to data published in Rheumatology.

A small minority of patients with familial Mediterranean fever may be able to achieve colchicine-free remission, according to data published in Pediatric Rheumatology.

In patients with juvenile fibromyalgia, pain distribution throughout the body may be less important for clinical outcomes and impairment than other factors, according to data published in Arthritis Care & Research.

Family history of autoimmune disease is a risk factor for developing of juvenile idiopathic arthritis, although it does not impact disease severity or course, according to data published in Pediatric Rheumatology.